Skip to Content

About Revance

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation investigational neuromodulator product, DaxibotulinumtoxinA for Injection. We are building a premium category in facial aesthetics, focused on differentiated and improved outcomes, a compelling value proposition and an elevated experience for physicians and patients.

DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. For use in aesthetic medicine, Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including forehead lines and lateral canthal lines (crow’s feet).

Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products and services, as well as therapeutics offerings. If approved, Revance’s therapeutics programs will bring innovation to multiple indications, with a current focus in muscle movement disorders including some debilitating conditions. DaxibotulinumtoxinA for Injection is currently being evaluated in a Phase 3 clinical program in cervical dystonia, including the completed ASPEN-1 and completed ASPEN-OLS trials, and has been studied in a Phase 2 (JUNIPER) trial in adult upper limb spasticity. The positive results of the ASPEN-1 topline readout underpinned the next stage of Revance’s growth beyond aesthetics and the positive data from the JUNIPER Phase 2 topline readout further validate Revance as an innovation leader in both the aesthetics and therapeutic markets.

To accompany DaxibotulinumtoxinA for Injection in the Aesthetics market, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and OPUL a relational commerce platform, which includes integrated smart payment, subscription and loyalty digital services.

Revance has also partnered with Mylan N.V. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace.

Revance is dedicated to making a difference by transforming patient experiences and is positioned to be an innovation leader not only in aesthetics, but also in therapeutics.

Our mission is to achieve the highest levels of excellence in all we do, by living our values–speed, authenticity, audacity, grit and empathy–as we set the new standard in healthcare.

Back to top